Piper Sandler on Akebia Therapeutics (AKBA): 'Continue to Like the Setup; Remain Buyers'
Tweet Send to a Friend
Piper Sandler analyst Allison M. Bratzel reiterated an Overweight rating and $6.00 price target on Akebia Therapeutics (NASDAQ: AKBA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
